SPRC SciSparc
- 0.2379
- -0.0002-0.08%
SciSparc News
SciSparc Ltd. Reports Changes in Financial Position
SciSparc | 6-K: Report of foreign private issuer (related to financial reporting)
SciSparc Ltd. Gains Shareholder Approval for Proposals
SciSparc Ltd. Reschedules Annual General Meeting
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
SciSparc Receives FDA Approval To Launch Pivotal Phase IIb Trial For Tourette Syndrome Treatment SCI-110 In U.S., Following Promising Phase IIa Results Showing Up To 40% Tic Reduction
SciSparc Ltd. Proposes Reverse Stock Split
SciSparc: Amitay Weiss Also Serves as Chairman of Bd of Directors of Purchaser >SPRC
SciSparc Will Receive Cash Consideration of $700,000 in Exchange for Shrs That Constitute 27% of MitoCareX Ownership >SPRC
SciSparc: Intended Selling Valuation Represents Increase of 47% From Valuation at Time of Initial Investment in MitoCareX Bio >SPRC
Express News | Scisparc Ltd - Additional Milestones Could Increase Consideration to $7 Mln
Express News | Scisparc Ltd - Owns 52.73% of Mitocarex
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
Express News | Scisparc Signs Non-Binding Letter of Intent to Sell Stake in Mitocarex
Express News | Scisparc Ltd - FDA Confirms Scisparc's Study May Proceed
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
SciSparc Takes Major Step Forward With IND Application Submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
Express News | Scisparc Takes Major Step Forward With Ind Application Submitted to the FDA for Phase Iib Clinical Trial for Tourette Syndrome Treatment
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Clearmind Applies for Patent on Anti-Addiction Combination Therapy -- Shares Up After Hours
Analysis
Price Target
No Data
No Data